Actavis Inc. said Tuesday it is once again selling a generic version of Bayer's oral contraceptive Yaz because a federal appeals court overturned one of the patents supporting the drug.
Actavis' generic is called Vestura. The company began selling it in January 2012, but took the drug off the market in March of that year after a federal court in Nevada upheld the patent. That decision has now been overturned by the U.S. Court of Appeals for the Federal Circuit.
Actavis said U.S. sales of brand-name and generic Yaz were about $347 million over the 12 months that ended Feb. 28.
Shares of Actavis rose 94 cents to close at $96.97.